Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (274)
- COVID-19 (163)
- Safety monitoring and information (99)
- Legislation (93)
- Compliance and enforcement (67)
- Vaping hub (53)
- Manufacturing (52)
- Labelling and packaging (35)
- Scheduling (national classification system) (27)
- Import and export (26)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1260 result(s) found, displaying 151 to 175
-
News articlesYour feedback is essential to shaping a user-friendly website that works better for everyone.
-
Safety updatesAdditional safety information is being added to all montelukast products to strengthen and highlight existing warnings about serious neuropsychiatric events.
-
Regulatory decision noticesThis consent is given under sections 14 and 14A of the Therapeutic Goods Act 1989.
-
Regulatory decision noticesThis instrument is made under subsections 19(5AA), 32CM(1A) and 41HC(1A) of the Therapeutic Goods Act 1989.
-
Therapeutic Goods (Special Access Scheme - Application and Notification Forms) Approval (No. 2) 2024
Regulatory decision noticesThis instrument is made under the Therapeutic Goods Regulations 1990, the Therapeutic Goods (Medical Devices) Regulations 2002 and the Therapeutic Goods Act 1989. -
Media releasesThe defendant faces a maximum penalty of 12 months’ imprisonment and/or a fine of up to $222,000 for each charge.
-
News articlesRecall reforms program update and preview of the PRAC Version 1.0.
-
Media releasesWe have issued infringement notices totalling $37,560 for the alleged unlawful possession of a commercial quantity of vaping goods.
-
Safety updatesTCMs sold in Australia are carefully regulated to ensure safety and quality.
-
Media releasesThe TGA and cooperating agencies have seized a large volume of alleged illicit vapes, tobacco and other substances in coordinated operations across Australia.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
News articlesFind out about new requirements for labels of injectable electrolyte medicines and updates to guidance for medicine sponsors.
-
Regulatory decision noticesMRA GMP clearances that are expiring on 31 December 2024 will be automatically extended.
-
BlogIf your business sells or advertises paracetamol, then you need to be aware of the new rules around pack sizes that commence on 1 February 2025.
-
BlogWe know that paracetamol is safe and effective for most people when taken at the recommended dose.
-
Regulatory decision noticesThis instrument is made under section 39 of the current Poisons Standard.
-
Regulatory decision noticesThis instrument is made under section 39 of the current Poisons Standard.
-
Regulatory decision noticesWe are providing a 12-month period of labelling exemptions for signal words for certain Pharmacy medicine and Pharmacist Only medicine products.
-
News articlesWe have introduced new features to improve your experience using Guidance on our website.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesHealth professionals and consumers are advised that the oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be used in children under 6 years of age.
-
Media releasesThe TGA has settled judicial review proceedings brought by InstantScripts in respect of infringement notices issued to it by the TGA.
-
Media releasesIn a significant move against the illicit vaping market, the TGA has played a vital role in joint enforcement activity with Victoria Police, resulting in the seizure of 200,000 vapes, worth more than $8 million
-
Safety updatesWe have received Australian reports of Guillain-Barré Syndrome (GBS) following Shingrix vaccination.
-
Media releasesTGA has taken further action to combat the unlawful sale of vapes in Queensland, issuing an infringement notice to a retailer for the unlawful possession of a commercial quantity of vaping goods